Gestational Diabetes Mellitus (GDM) affects approximately 6–9% of pregnancies in the United States, with rates rising globally due to increasing maternal age and obesity prevalence. This metabolic disorder, characterized by glucose intolerance first recognized during pregnancy, carries significant short- and long-term risks for both mother and offspring—including preeclampsia, cesarean delivery, neonatal hypoglycemia, and a markedly elevated lifetime risk of type 2 diabetes. Early detection through universal screening between 24 and 28 weeks of gestation, followed by prompt and effective management, substantially reduces these adverse outcomes.

While obstetricians, endocrinologists, and diabetes educators have traditionally led GDM care, pharmacists represent an underutilized yet uniquely positioned resource in this ecosystem. With over 300,000 community pharmacists in the United States alone, and millions more worldwide, these professionals are often the most accessible healthcare providers for pregnant women—many of whom visit a pharmacy weekly for prenatal vitamins, over-the-counter remedies, or prescription medications. This consistent point of contact creates an extraordinary opportunity for pharmacists to contribute meaningfully to GDM screening education, risk assessment, and ongoing support. This article examines the multifaceted contributions pharmacists can make across the GDM care continuum and offers practical strategies for integrating pharmacy services into standard prenatal care.

Understanding Gestational Diabetes: A Growing Public Health Priority

GDM arises when placental hormones induce insulin resistance that surpasses the pancreatic beta-cells' compensatory capacity. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study established a continuous relationship between maternal glucose levels and adverse outcomes, leading to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria now adopted by many organizations worldwide. Under these criteria, GDM is diagnosed when any one of the following plasma glucose values is met or exceeded during a 75-gram oral glucose tolerance test (OGTT): fasting ≥ 92 mg/dL, 1-hour ≥ 180 mg/dL, or 2-hour ≥ 153 mg/dL.

Risk factors for GDM include maternal age over 25 years, body mass index (BMI) ≥ 25 kg/m², family history of type 2 diabetes, history of GDM in a prior pregnancy, history of delivering an infant weighing > 4,000 grams (macrosomia), and membership in high-risk ethnic groups (Hispanic, African American, Native American, South or East Asian, and Pacific Islander populations). Alarmingly, up to 40% of women with GDM will develop type 2 diabetes within five to ten years postpartum, highlighting the importance of the diagnosis as an opportunity for early intervention and prevention.

The economic burden of GDM is substantial. A 2020 systematic review estimated that the incremental cost of a GDM-affected pregnancy in the United States ranges from $2,000 to $6,000, driven largely by increased rates of cesarean delivery, neonatal intensive care admissions, and long-term maternal metabolic disease. Effective screening and management programs can reduce these costs while improving outcomes—a value proposition that aligns perfectly with pharmacy's expanding public health role.

Pharmacists as Accessible Frontline Educators for GDM Screening

Identifying At-Risk Populations in the Community Pharmacy Setting

Community pharmacists interact daily with women of reproductive age who may be unaware of their GDM risk status. During routine encounters—such as prenatal vitamin purchases or minor ailment consultations—pharmacists can conduct brief risk assessments using validated tools. For instance, the American Diabetes Association (ADA) provides a simple risk test that pharmacists can administer in less than two minutes, covering age, weight, family history, and prior pregnancy complications. Women identified as high-risk can be referred to their obstetric provider for early screening, ideally at the first prenatal visit rather than waiting until the standard 24–28 week window.

Pharmacists can also leverage prescription fill data to identify patients who may be at elevated risk. A woman filling medications for conditions associated with insulin resistance—such as polycystic ovary syndrome (PCOS), hypertension, or dyslipidemia—represents a prime candidate for GDM risk discussion. Similarly, women prescribed metformin or other glucose-lowering agents before pregnancy warrant careful monitoring and early screening. By integrating these clinical cues into standard workflow, pharmacies can transform a routine transaction into a proactive health intervention.

Demystifying the Oral Glucose Tolerance Test (OGTT)

Despite its established utility, the OGTT remains poorly understood by many pregnant women, leading to anxiety, non-adherence, and avoidable rescheduling. Pharmacists can address this knowledge gap through clear, patient-centered education delivered at the point of care. Key teaching points include the importance of consuming at least 150 grams of carbohydrates daily for three days before the test (to ensure reliable results), the need for a 8–12 hour fast, the procedure itself (blood draw, ingestion of 75-gram glucose beverage, waiting period, and second blood draw), and common side effects such as nausea or lightheadedness.

Pharmacists can also prepare women for the possibility of abnormal results, framing GDM not as a failure but as a manageable condition with excellent pregnancy outcomes when properly controlled. This proactive counseling reduces psychological distress and improves readiness to engage in treatment if diagnosed. For women who have experienced previous GDM, pharmacists can reinforce the importance of early screening in subsequent pregnancies, as recurrence rates range from 30% to 84% depending on risk factors and interpregnancy weight change.

Addressing Barriers to Screening Uptake

Despite guideline recommendations, GDM screening rates remain suboptimal in many communities, particularly among uninsured or underinsured populations, racial and ethnic minorities, and women with limited health literacy. Pharmacists can help overcome these barriers through targeted outreach and tailored education. For example, offering pharmacy-based GDM screening services—where permitted by state scope-of-practice regulations—can increase access for women who face transportation challenges, inflexible work schedules, or language barriers in traditional healthcare settings.

In states where pharmacists have collaborative practice agreements (CPAs) or autonomous prescriptive authority, they may be able to order and interpret OGTTs directly, reducing the need for separate physician visits. Even where such authority is limited, pharmacists can serve as navigators, helping women schedule appointments, understand insurance coverage for screening, and prepare documentation for their healthcare providers. This supportive role is especially valuable in rural and underserved areas, where obstetric providers may be scarce and pharmacies serve as de facto health hubs.

Comprehensive Education for Women Diagnosed with GDM

A diagnosis of GDM can be overwhelming, triggering anxiety, guilt, and confusion about the path forward. Pharmacists are well positioned to provide immediate, accessible education that complements the care delivered by obstetricians and diabetes specialists. This education should span medication management, blood glucose monitoring, nutrition, physical activity, and psychosocial support.

Medication Management and Safety Counseling

While many women with GDM achieve glycemic targets through lifestyle modification alone, approximately 15–30% require pharmacotherapy. Insulin remains the first-line agent recommended by most professional organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the ADA, because it does not cross the placenta in significant amounts and has an established safety record spanning decades. Pharmacists play an essential role in insulin counseling—covering injection technique, syringe/pen device education, dose timing relative to meals, storage guidelines, and recognition of hypoglycemia symptoms (shakiness, sweating, confusion, hunger).

Oral hypoglycemic agents, particularly metformin and glyburide, are used off-label for GDM in many settings, though their long-term safety data remain less robust than for insulin. Pharmacists must be prepared to discuss the evidence—and the gaps in evidence—with patients and their providers. For example, glyburide crosses the placenta and has been associated with higher rates of neonatal hypoglycemia and macrosomia compared to insulin in some studies. Metformin crosses the placenta but has not been linked to major teratogenic effects, though long-term metabolic outcomes in offspring are still under investigation. Pharmacists can facilitate shared decision-making by presenting balanced information that respects patient values and preferences while emphasizing safety.

Beyond diabetes-specific medications, pharmacists should review all prescription and over-the-counter products for potential interactions or contraindications in GDM. Corticosteroids, beta-agonists, certain antipsychotics, and some antihypertensives can worsen glucose tolerance and may require dose adjustment or alternative selection during pregnancy. Similarly, herbal supplements and natural products—which many women use without disclosing to their healthcare team—may affect blood glucose levels or interact with prescribed therapies. A thorough medication reconciliation at the time of GDM diagnosis and at regular intervals throughout pregnancy is an indispensable service that only pharmacists are consistently trained and positioned to provide.

Blood Glucose Monitoring Training and Support

Self-monitoring of blood glucose (SMBG) is a cornerstone of GDM management, yet many women receive inadequate training on how to use a glucose meter, interpret results, and take appropriate action. Pharmacists can fill this gap through hands-on device education, including proper fingerstick technique, calibration, coding (for older meters), and data logging or downloading. Teaching women to identify patterns—such as consistently elevated fasting glucose (suggesting hepatic insulin resistance) versus postprandial spikes (related to carbohydrate intake)—empowers them to make proactive adjustments in collaboration with their care team.

Pharmacists can also help women establish realistic and sustainable monitoring schedules. Typical recommendations include fasting measurements upon waking and one- or two-hour postprandial measurements after each meal, totaling four or more checks daily. This frequency can feel burdensome, particularly for women with demanding jobs or childcare responsibilities. Pharmacists can suggest strategies to integrate monitoring into daily routines—such as testing before brushing teeth in the morning or immediately after finishing a meal—and reinforce that the discomfort and inconvenience are temporary investments in the health of both mother and baby.

Target glucose ranges vary by organization but generally fall within 70–95 mg/dL for fasting and 140 mg/dL or less at one hour postprandial (or 120 mg/dL or less at two hours). Pharmacists should ensure women know their personal targets, understand how to respond to out-of-range values, and recognize when to contact their provider for medication adjustment. For women using insulin, pharmacists can review strategies for managing nocturnal hypoglycemia and the "Somogyi phenomenon" (rebound hyperglycemia following an untreated nocturnal low), which is often misinterpreted as insufficient insulin dosing.

Nutritional Counseling and Lifestyle Guidance

Medical nutrition therapy (MNT) is the foundation of GDM treatment, with carbohydrate management at its core. While registered dietitians are the primary providers of MNT, pharmacists can reinforce key dietary principles during every patient interaction. The fundamental message is not carbohydrate elimination, but rather carbohydrate distribution—spreading intake across three meals and two to three snacks to avoid large postprandial glucose excursions. The ADA recommends that women with GDM consume approximately 175 grams of carbohydrates per day (on the low end of the 175–210 gram range for pregnancy), with emphasis on high-fiber, low-glycemic-index sources such as whole grains, legumes, vegetables, and fruits.

Pharmacists can provide practical guidance on reading nutrition labels, identifying hidden sugars, and making healthier choices when eating out or purchasing prepared foods. They can also address common misconceptions, such as the belief that all fruits should be avoided (in reality, whole fruits with skin—apples, pears, berries—are generally well-tolerated) or that "sugar-free" products are automatically safe (many contain sugar alcohols that can cause gastrointestinal distress or artificial sweeteners with uncertain safety profiles in pregnancy).

Physical activity is the other major lifestyle lever for GDM management, with evidence showing that 30 minutes of moderate-intensity aerobic activity most days of the week improves insulin sensitivity and glycemic control. Pharmacists can encourage women to find activities they enjoy—walking, swimming, stationary cycling, prenatal yoga—while observing standard pregnancy precautions such as avoiding supine exercise after the first trimester and staying hydrated. For women with contraindications to exercise (such as preterm labor risk, placenta previa, or severe hypertension), pharmacists should reinforce the importance of following their obstetric provider's guidance while still optimizing other aspects of management.

Postpartum Care and Long-Term Prevention Strategies

The immediate postpartum period represents both a high-risk window and a critical opportunity for intervention. Women with GDM have a 40–60% risk of developing type 2 diabetes within a decade, yet many do not receive recommended postpartum screening or preventive care. Pharmacists can help close this gap through structured follow-up and education that begins during pregnancy and continues after delivery.

Postpartum Glucose Testing and Diabetes Prevention

The ADA and ACOG recommend that all women with GDM undergo a 75-gram OGTT at 4–12 weeks postpartum to assess for persistent glucose intolerance. Despite this guideline, data from the CDC show that only about 50% of women complete this test. Pharmacists can promote adherence by discussing the importance of postpartum screening throughout pregnancy, providing written reminders, and—where scope permits—ordering the test directly or facilitating referral to a laboratory.

Women who are found to have prediabetes or type 2 diabetes at postpartum screening require immediate referral for ongoing diabetes care and intensive lifestyle intervention. Those with normal glucose tolerance should be counseled on their elevated lifetime risk and the importance of regular screening every one to three years, maintaining a healthy weight, and adopting diabetes prevention strategies. The landmark Diabetes Prevention Program (DPP) demonstrated that lifestyle intervention reduced the incidence of type 2 diabetes by 58% in women with a history of GDM—a benefit that exceeded even metformin therapy. Pharmacists can connect women with community-based DPP programs, many of which are now offered remotely and are covered by Medicare and many commercial insurers.

Interconception Care and Future Pregnancy Planning

For women planning additional pregnancies, achieving optimal health before conception is essential. Pharmacists can counsel women with prior GDM on the importance of achieving a healthy BMI, optimizing blood glucose and A1C levels, and ensuring adequate folic acid intake (400–800 mcg daily for primary neural tube defect prevention, with higher doses for women with elevated BMI or prior affected pregnancies). Preconception counseling should also address medication modifications—for example, switching from statins or ACE inhibitors to pregnancy-safe alternatives for women with concurrent hypertension or dyslipidemia.

Breastfeeding is another area where pharmacists can offer targeted support. Beyond its established benefits for infant health, breastfeeding improves maternal glucose metabolism and may reduce the risk of progression to type 2 diabetes after GDM. Pharmacists can encourage women to breastfeed exclusively for at least six months when possible, offer guidance on common breastfeeding challenges, and review the safety of diabetes medications during lactation. Insulin and metformin are considered compatible with breastfeeding, while glyburide should be used with caution due to limited safety data.

Integrating Pharmacy into Collaborative GDM Care Models

No single provider can address all the needs of a woman with GDM. Optimal care requires a coordinated team that may include the obstetrician, endocrinologist or diabetologist, registered dietitian, diabetes educator, and pharmacist. Pharmacists contribute unique value through their medication expertise, accessibility, and patient trust—but realizing this potential requires intentional integration into existing care pathways.

Establishing Collaborative Practice Agreements for GDM

Collaborative Practice Agreements (CPAs) are formal documents that allow pharmacists to initiate, modify, or monitor medication therapy under a supervising physician's protocol. In the context of GDM, a CPA might authorize a pharmacist to adjust insulin doses based on a patient's blood glucose logs, initiate metformin therapy for women with prediabetes postpartum, or order and interpret OGTTs for screening and diagnosis. Such agreements are already in place in many states for conditions like hypertension, hyperlipidemia, and anticoagulation—extending them to GDM is a natural progression.

Developing a GDM CPA requires collaboration between the pharmacy team and local obstetric providers. Key elements include clear patient inclusion and exclusion criteria, standardized treatment algorithms based on evidence-based guidelines, defined communication protocols (e.g., when to contact the physician for non-protocol scenarios), and documentation requirements. Pharmacies that have implemented similar programs report high patient satisfaction, improved clinical outcomes, and strengthened relationships with referring providers.

Pharmacy-Based GDM Education and Monitoring Programs

Beyond CPAs, pharmacies can establish structured education and monitoring programs that operate in parallel with—and complement—medical care. These programs might include a series of individual or group counseling sessions covering the topics discussed in this article: risk assessment and screening preparation (early pregnancy), medication management and blood glucose monitoring (at diagnosis), and postpartum screening and prevention (third trimester and after delivery). Pharmacies can use their existing patient engagement platforms—such as medication synchronization programs, adherence packaging, or text messaging services—to deliver timely reminders and education.

Several retail pharmacy chains have already piloted such programs with encouraging results. For example, a 2021 study published in the Journal of the American Pharmacists Association found that a pharmacist-led GDM education program significantly improved patients' knowledge scores and self-care behaviors compared to usual care. Another study from the United Arab Emirates demonstrated that pharmacist counseling reduced cesarean section rates and neonatal intensive care admissions among women with GDM. These findings underscore the potential for pharmacy services to produce measurable improvements in maternal and neonatal outcomes.

Overcoming Barriers to Full Pharmacy Engagement

Despite the clear opportunities, several barriers limit the full integration of pharmacists into GDM care. These include regulatory restrictions on scope of practice, limitations in pharmacist education and training, lack of reimbursement for clinical services, and insufficient integration with electronic health records and referral systems.

Addressing these barriers requires action at multiple levels. At the state and national level, pharmacy organizations should advocate for expanded scope of practice that includes ordering and interpreting laboratory tests, initiating and adjusting medications under protocol, and billing for clinical services (including incident-to billing for services provided under a CPA, or direct billing via pharmacist-specific Current Procedural Terminology [CPT] codes). At the educational level, pharmacy schools and continuing education providers should offer robust training in maternal health, including GDM management, motivational interviewing, and interprofessional communication. At the practice level, pharmacies should invest in training, workflow redesign, and technology that supports clinical service delivery—such as private counseling rooms, blood glucose monitors for demonstration, and integration with health information exchanges.

Reimbursement remains a significant hurdle. While Medicare Part B covers diabetes self-management training and medical nutrition therapy under certain conditions, these services are typically provided by nurses and dietitians, not pharmacists. Some commercial insurers have begun to recognize pharmacist-provided clinical services, but coverage is inconsistent and often limited to medication therapy management (MTM). Pharmacy advocates continue to push for broader recognition of pharmacist value in maternal health, and early adopters have demonstrated that even without direct reimbursement, the downstream revenue from increased patient loyalty, improved adherence, and enhanced reputation can offset program costs.

Conclusion: A Call to Action for the Pharmacy Profession

Gestational diabetes mellitus represents a significant and growing public health challenge—but also a profound opportunity for pharmacy to demonstrate its value in maternal health. Pharmacists are already embedded in the communities where women live, work, and seek care. They hold the trust of their patients and possess the clinical knowledge to make a difference at every stage of the GDM care continuum: from risk identification and screening education, through diagnosis and treatment management, to postpartum prevention and interconception care.

What has been lacking, in many cases, is the intentional design of systems and workflows that enable pharmacists to act on this potential. The path forward is clear: develop collaborative relationships with obstetric providers, create structured education programs that can be delivered consistently across all pharmacy touchpoints, advocate for regulatory and reimbursement changes that recognize pharmacist contributions, and invest in the training and technology needed to support this work. Organizations such as the American Pharmacists Association, the American Diabetes Association, and the Centers for Disease Control and Prevention offer resources, guidelines, and advocacy support for pharmacists seeking to expand their role in GDM care.

The benefits of such efforts are clear: better health outcomes for mothers and babies, reduced healthcare costs, and a stronger, more integrated healthcare system. For the individual pharmacist, engaging with GDM care offers a deeply rewarding opportunity to make a lasting difference in the health of families. The question is no longer whether pharmacists can contribute meaningfully to GDM care—the evidence is compelling that they can. The question is whether the profession will seize this opportunity with the urgency and commitment it deserves.

Every pregnancy is a journey. For women with GDM, that journey is complicated by anxiety, risk, and the daily demands of glucose monitoring and lifestyle management. By stepping into a more active role in screening, education, and support, pharmacists can become trusted guides on that journey—helping women navigate the challenges of GDM and emerge healthier on the other side, equipped with the knowledge and habits to sustain their well-being for a lifetime.